Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal

Paliperidone palmitate 3-monthly (PP3M), an approved maintenance treatment for patients with schizophrenia, was the first long-acting antipsychotic injectable (LAI) to require only four administrations per year. Here, we aimed to review the available evidence about its use in the management of schiz...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Carmona, Juan Antonio, Pappa, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504906/
https://www.ncbi.nlm.nih.gov/pubmed/37720806
http://dx.doi.org/10.2147/DHPS.S339170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504906/
https://www.ncbi.nlm.nih.gov/pubmed/37720806
http://dx.doi.org/10.2147/DHPS.S339170

Ejemplares similares